Panelists highlight that menin inhibitors represent a breakthrough in the treatment of KMT2A-rearranged AML by targeting the disease’s core epigenetic drivers, with early clinical trials like ...
A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...
TUS+VEN+AZA therapy shows promising safety and efficacy in newly diagnosed AML patients ineligible for induction chemotherapy. Early TUSCANY trial results indicate complete remission in patients, ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results